Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Jul 1;160(7):763-770.
doi: 10.1001/jamasurg.2025.1299.

Hemodynamic Impact of Cipepofol vs Propofol During Anesthesia Induction in Patients With Severe Aortic Stenosis: A Randomized Clinical Trial

Tingting Ni  1 , Xiaoxia Zhou  1 , Shuguang Wu  1 , Tao Lv  2 , Yujiao Hu  1 , Qi Gao  1 , Ge Luo  1 , Chen Xie  1 , Jingcheng Zou  1 , Yuexiu Chen  1 , Linqian Zhao  1 , Jie Xiao  1 , Xincheng Tao  1 , Yu Yi  1 , Zhili Xu  1 , Tingting Wang  1 , Junyu Zhou  1 , Yuanyuan Yao  1 , Min Yan  1
Affiliations
Randomized Controlled Trial

Hemodynamic Impact of Cipepofol vs Propofol During Anesthesia Induction in Patients With Severe Aortic Stenosis: A Randomized Clinical Trial

Tingting Ni et al. JAMA Surg. .

Abstract

Importance: Postinduction hemodynamic instability is a frequent complication among patients with severe aortic stenosis (AS). Using cipepofol as the anesthesia agent may reduce the incidence and severity of hemodynamic instability.

Objective: To assess whether cipepofol outperforms propofol in maintaining postinduction hemodynamic stability in patients with AS.

Design, setting, and participants: This single-center, randomized clinical trial was conducted from June 29, 2023, to July 8, 2024, at the Second Affiliated Hospital of Zhejiang University School of Medicine in China. Patients with AS scheduled for transcatheter aortic valve replacement (TAVR) were eligible for inclusion.

Interventions: Participants were randomized 1:1 to receive either cipepofol or propofol as anesthesia induction agents at equipotent doses.

Main outcomes and measures: The primary outcome was the area under the curve (AUC) of the mean arterial pressure (MAP) difference from baseline during the initial 15 minutes postinduction.

Results: A total of 124 patients with AS scheduled for TAVR were randomized into either the cipepofol group (n = 62) or the propofol group (n = 62). Of 124 patients randomized, 1 patient from each group was excluded due to ineligibility for the TAVR procedure, and data were analyzed for 122 patients (61 patients per group) based on the intention-to-treat principle. Among 122 total patients, mean (SD) age was 72.2 (5.0) years, and 53 patients (43.4%) were female. The cipepofol group exhibited a significantly smaller median (IQR) AUC (-8505.0 mm Hg · s [-12 402.8 to -5130.0]) compared with the propofol group (-13 189.0 mm Hg · s [-17 006.7 to -7593.3]; P < .001). Moreover, compared with the propofol group, the cipepofol group demonstrated a significantly lower incidence of postinduction hypotension (70.5% vs 88.5%; P = .01) and required a smaller median (IQR) dose of norepinephrine during the first 15 minutes postinduction (6.0 μg [0.0-10.0] vs 10.0 μg [5.0-20.0]; P = .006). Additionally, the 2 groups' bispectral indices were comparable.

Conclusions and relevance: In this randomized clinical trial, cipepofol provided superior hemodynamic stability as an induction agent compared to propofol at equipotent doses and similar anesthesia depths for patients with AS. Therefore, cipepofol could serve as an alternative induction agent to propofol for patients at high cardiovascular risk.

Trial registration: ClinicalTrials.gov Identifier: NCT05881291.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.
Figure 1.. CONSORT Diagram
BMI indicates body mass index (calculated as weight in kilograms divided by height in meters squared); TAVR, transcatheter aortic valve replacement. SI conversion factor: To convert hemoglobin from g/dL to g/L, multiply by 10.
Figure 2.
Figure 2.. Changes in Mean Arterial Pressure (MAP) During the First 15 Minutes Postinduction for Cipepofol and Propofol Groups
See this image and copyright information in PMC

Comment on

References

    1. Toff WD, Hildick-Smith D, Kovac J, et al. ; UK TAVI Trial Investigators . Effect of transcatheter aortic valve implantation vs surgical aortic valve replacement on all-cause mortality in patients with aortic stenosis: a randomized clinical trial. JAMA. 2022;327(19):1875-1887. doi: 10.1001/jama.2022.5776 - DOI - PMC - PubMed
    1. Nakanishi T, Tsuji T, Sento Y, Hashimoto H, Fujiwara K, Sobue K. Association between postinduction hypotension and postoperative mortality: a single-centre retrospective cohort study. Can J Anaesth. 2024;71(3):343-352. doi: 10.1007/s12630-023-02653-6 - DOI - PMC - PubMed
    1. Jor O, Maca J, Koutna J, et al. Hypotension after induction of general anesthesia: occurrence, risk factors, and therapy. a prospective multicentre observational study. J Anesth. 2018;32(5):673-680. doi: 10.1007/s00540-018-2532-6 - DOI - PubMed
    1. Reich DL, Hossain S, Krol M, et al. Predictors of hypotension after induction of general anesthesia. Anesth Analg. 2005;101(3):622-628. doi: 10.1213/01.ANE.0000175214.38450.91 - DOI - PubMed
    1. Südfeld S, Brechnitz S, Wagner JY, et al. Post-induction hypotension and early intraoperative hypotension associated with general anaesthesia. Br J Anaesth. 2017;119(1):57-64. doi: 10.1093/bja/aex127 - DOI - PubMed

Associated data